RA Capital Management is a Boston-based investment firm focused on healthcare, life sciences, and planetary health, investing in public and private companies across stages from seed to late-stage financings. The firm emphasizes evidence-based, science-led investing guided by internal research capabilities, including TechAtlas. It operates Raven, a biomedical innovation incubator that supports entrepreneurs and developers, and pursues value creation through collaborative partnerships, often co-investing and taking board positions. With a multidisciplinary, data-driven approach, RA Capital seeks to back management teams from inception through commercialization and beyond, aiming to improve patient outcomes and advance medical innovation.

OrbiMed is a global healthcare-focused investment firm founded in 1989 and headquartered in New York. It manages assets across public and private markets and pursues opportunities across the healthcare spectrum, including biopharmaceuticals, medical devices, diagnostics, digital health, and health services. The firm invests in startups, growth-stage companies, and established entities, leveraging scientific and medical expertise to support development and commercialization. It also offers financing solutions such as structured debt and royalty monetization for intellectual property and medical diagnostics.

Eli Lilly and Company is a global pharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines across neuroscience, cardiometabolic, cancer, and immunology areas. It operates manufacturing and distribution facilities in the United States, Puerto Rico, and about 25 other countries, with products sold in roughly 135 countries. The company emphasizes ongoing research to create therapies that address unmet medical needs and to improve patient outcomes. Its portfolio spans treatments for diabetes and metabolic conditions, cancer, autoimmune diseases, and other serious conditions.

Founded in 1985, The Invus Group is a global private equity firm that partners with entrepreneurs, founders and management teams across the company lifecycle. Blending a family-office approach with multi-strategy investing, it supports transformative growth in sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education and medical devices. The firm pursues long-term value creation through strategic insight, capital and execution, investing in companies from early stages to mature businesses and providing both lead investments and co-investments in private transactions worldwide. It maintains a global footprint with offices in New York, London, Paris and Hong Kong and has a flexible structure designed to align incentives with partners over time.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. The firm manages approximately $5.8 billion in assets under management and has invested in over 290 public and private healthcare companies worldwide. Its multi‑fund platform covers growth equity, private equity including buyouts, venture capital, and public equity, and it makes investments across biotechnology, pharmaceuticals, medical devices, and healthcare services in major markets, with a focus on the United States and China. The team comprises about 50 professionals including physicians, scientists, entrepreneurs, operating executives, and industry experts who collaborate to build and grow high‑quality healthcare companies.

Novo Nordisk is a global pharmaceutical company headquartered in Denmark that discovers, develops, manufactures, and markets medicines primarily for diabetes care and related chronic diseases. Its portfolio includes insulin therapies and other diabetes treatments, with a growing focus on obesity management, growth disorders, haemophilia, and cardiovascular conditions. The company emphasizes research and development to advance innovative therapies, including metabolic and cardiometabolic medicines, and aims to expand access to essential medicines worldwide. Novo Nordisk places a strong emphasis on patient safety, sustainability, governance, and transparent reporting, reflecting responsible business practices and ESG commitments. Operating globally, it pursues collaborations and partnerships to address global health needs and strives to improve health outcomes through scientific excellence and responsible stewardship of resources.

Samsara BioCapital is a Palo Alto-based venture capital firm focused on biotechnology and transformative therapeutics. Founded in 2016, it invests in the healthcare sector across the United States and operates as an investment adviser. The firm collaborates with scientists, physicians, drug developers, and business leaders to support ambitious biotechnology companies and advance a portfolio of therapeutic projects aimed at delivering innovative medicines to patients.

Qiming Venture Partners is a global venture capital firm founded in 2006 with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages multiple funds and more than $9.5 billion in committed capital, investing across healthcare, information technology, new consumer patterns, mobile internet, AI, robotics, and related sectors. The firm backs early to growth-stage companies, including numerous healthcare, tech and consumer businesses, and has built a broad portfolio exceeding several hundred companies with a substantial track record of exits, including IPOs and M&A. It operates a U.S. presence to back cross-border opportunities and emphasizes a hands-on approach, leveraging industry resources and an extensive network to support portfolio companies through strategic decisions, governance, and scaling. The portfolio spans marquee names and innovative startups, reflecting a focus on accelerating China's innovation and delivering long-term value for entrepreneurs and stakeholders.

Venrock is a Palo Alto-based venture capital firm, founded in 1969 as the venture capital arm of the Rockefeller family. It focuses on seed and early-stage investments in technology and healthcare, supporting founders with strategic guidance and long-term growth. The firm has backed a broad portfolio of notable companies across software, semiconductors, healthcare, and consumer technology, including Apple, Intel, Illumina, Nest, Gilead Sciences, DoubleClick, Athenahealth, Endeca, SlideShare, and Tudou. With offices in Silicon Valley and New York, Venrock emphasizes partnership with entrepreneurs to build enduring companies through hands-on mentorship, sector expertise, and a long-term orientation. Its activity spans multiple technology and life sciences domains, including cybersecurity, AI, and digital health, reflecting a consistent track record of helping portfolio companies scale and achieve exits.

New Enterprise Associates is a United States-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across multiple stages, from seed to growth and IPO, and provides strategic support in product development and market expansion. The firm targets sectors including software, AI, consumer technology, digital health, life sciences, and energy technology, and pursues opportunities worldwide. NEA emphasizes long-term partnerships with founders, drawing on domain expertise and a broad network to help portfolio companies scale. It maintains a diverse portfolio across the United States, Asia and other regions, reflecting a global approach to venture investing.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven investments in life sciences, biotechnology, medical technologies, and related fields. The firm backs companies at multiple stages, often co-founded with scientists and entrepreneurs, aiming to translate academic research and national laboratory innovations into therapies, diagnostics, and other breakthrough technologies. ARCH emphasizes deep involvement, technical expertise, and a wide network to support founders from early development through later rounds, acting as a partner rather than a passive investor. With a focus on markets centered in the United States and North America, the firm frequently funds startups emerging from universities and research institutions and has built a track record of helping scientists bring innovations to market.

Deep Track Capital is a biotechnology investment firm based in Greenwich, Connecticut. It focuses on the life sciences and biotech sector, forging partnerships with management teams of innovative public and pre-IPO biotechnology companies, and aims to invest time, expertise, and its network alongside capital to support partners. The firm seeks to lead transactions while forming large syndicates and to participate in rounds led by other qualified investors.

Redmile Group is a San Francisco based investment firm specializing in healthcare, life sciences and related technology sectors. It pursues venture, growth, and crossover investments and provides strategic capital and operating experience to portfolio companies, supporting growth initiatives, acquisitions, and strategic partnerships. With offices in San Francisco and New York, the firm takes a hands-on approach, applying deep industry knowledge and networks to help portfolio companies scale and create long-term value for investors.

The European Innovation Council is a Brussels-based European Union organization established in 2018 to support deep‑tech innovation by helping startups, researchers and technology transfer activities move ideas toward market. It operates a portfolio of programs including Pathfinder, Accelerator, Transition, STEP Scale Up and Pre-Accelerator, and collaborates with partners to provide funding, mentorship and resources across the innovation lifecycle. The council emphasizes high-impact, science‑driven technologies with broad societal benefit and promotes inclusion, with initiatives to involve women‑led projects. It engages the wider ecosystem through awards, events and community initiatives and monitors impact through data platforms. By coordinating with private investors and other stakeholders, it aims to accelerate the scale-up of European deep‑tech firms and strengthen Europe’s position in global technology leadership.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco. It invests across the healthcare sector, including life sciences, biotechnology, pharmaceuticals, and medical devices, at all stages with an emphasis on discovery and development of novel therapeutics. The firm operates globally with offices in Canada, the United States, and Europe, delivering hands-on support to portfolio companies through in-house scientific and operating expertise. Versant pursues collaborative partnerships with entrepreneurs to translate research into clinical and commercial success and has a track record of portfolio companies achieving successful acquisitions or IPOs. The firm is registered as an investment adviser.

Logos Capital is a San Francisco-based biotechnology investment firm founded in 2019 that combines in-house data analytics with scientific and clinical expertise to identify transformative therapies. The firm uses a disciplined, data-driven approach and a proprietary Logos Analytics platform to model clinical data, assess likelihood of clinical success, and support comprehensive underwriting, ongoing event tracking, and proactive risk management. Its team spans medical, scientific, and business disciplines, with the aim of delivering long-term returns through investments in therapies that have the potential to improve patient outcomes and redefine standards of care.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. It provides seed through growth capital to life science and technology companies developing breakthrough therapies, diagnostics, research tools, agrifoodtech, agtech, digital health, and related platforms. Backed by the parent company’s industry experience and scientific advisory network, the firm leverages long-standing relationships and domain expertise to support early to growth-stage ventures aiming to translate scientific advances into practical healthcare and technology solutions.

Forbion is a venture capital firm based in Naarden, Netherlands, with over twenty years of experience investing in biotech and life sciences. It focuses on human health, planetary health, and the bioeconomy, supporting early-stage and growth investments across Europe and North America in drug development, MedTech, and sustainable solutions. Its portfolio includes gene therapy and other innovative therapies for rare diseases. Forbion manages funds totaling about €5 billion in committed capital across multiple vehicles and prioritizes ESG principles in its investment approach, seeking to accelerate scientific advances and drive long-term value for portfolio companies.

Deerfield Management is a New York City–based healthcare investment and information platform that advances health outcomes through flexible funding, data-driven insights, and philanthropic support. The firm invests in and builds healthcare companies across biotechnology, pharmaceuticals, diagnostics, medical devices, healthcare services, and digital health, leveraging a dedicated research and development engine, Deerfield Discovery and Development, and in-house facilities that support scientific collaboration and discovery. Its Intelligence offering uses AI, data and market research to drive technology and strategy across its portfolio and the broader healthcare ecosystem. Deerfield operates the Cure hub housing portfolio companies and modern labs, and has partnered with organizations such as Blue Cross Blue Shield of North Carolina to develop services like Alo that assist independent physicians in managing the business of medicine. The Deerfield Foundation funds education, healthcare access and health outcomes initiatives, reflecting a broader philanthropic approach to accelerating medical innovation through partnerships and strategic collaborations.

TCG Crossover is a science-driven healthcare investment firm focused on identifying and advancing disruptive medicines. The firm invests in private and public biotechnology and health-technology companies led by entrepreneurs pursuing innovative treatments, with investment teams based in Palo Alto and New York City. Its approach emphasizes supporting ventures that aim to improve patient outcomes and accelerate pharmaceutical development through a research-driven portfolio and strategic backing.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in building and funding early-stage biotechnology and life sciences companies, as well as technology ventures. Founded in 1980, it uses a seed-led venture creation approach to translate scientific discoveries into scalable medicines and biotech businesses, often acting as a lead investor and seeking board representation for portfolio companies.

Sofinnova Investments is a venture capital firm founded in 1976 and headquartered in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It backs life sciences and information technology companies across the United States and Europe, from seed through early and growth stages. In life sciences, it targets clinical-stage pharmaceutical and biotechnology companies, drug discovery platforms, and medical technology addressing diseases with unmet medical needs, including oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it supports product-oriented software, enterprise IT solutions and telecommunications infrastructure. The firm often requires board participation for early-stage lead or co-lead investments and emphasizes hands-on guidance to help entrepreneurs build global businesses.

SOSV is a global venture capital firm that provides early-stage and seed investments alongside structured accelerator programs and deeply resourced facilities to accelerate product development. Focused on deep tech, human and planetary health, and cross-border software, SOSV backs startups from pre-seed onward and runs programs that accelerate technical development, regulatory strategy, and fundraising. The firm maintains labs and engineering spaces with specialist staff in multiple regions, including the United States and Asia, to support portfolio companies in biosafety, chemistry, mechatronics, analytics, and electrical engineering. Programs such as HAX and other live events offer founders access to prototyping, testing, and investor networks. Annually, SOSV makes around sixty pre-seed investments (up to roughly $550k each) and participates in numerous follow-on rounds, leveraging a global portfolio and extensive co-investor network to help deeply technical startups scale and reach markets.

Pfizer is a leading global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines to address unmet medical needs. It maintains a broad portfolio across prescription medicines, vaccines, and treatments spanning internal medicine, inflammation and immunology, oncology, and other therapeutic areas, and it operates a sizable pipeline of investigational products with potential to address major diseases. The company conducts extensive global sales, with international markets contributing a substantial share of revenue, and it emphasizes scientific innovation, transparency, patient access, and ethical business practices. Its well-known products include Prevnar 13 and Eliquis, among others, and it continues to invest in research and development to advance new therapies. Based in the United States, Pfizer has a long history dating back to the 19th century and maintains a global footprint through manufacturing, partnerships, and philanthropic initiatives aimed at improving health outcomes worldwide.

Omega Funds is a Boston, Massachusetts-based venture capital firm focused on life sciences and healthcare investments across North America and Western Europe. The firm targets opportunities in the life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, leveraging an experienced team and broad network to support entrepreneurs and founders. It has facilitated the development of products reaching patients and has a track record that includes a public listing and an M&A deal. The firm operates across multiple funds and engages with the European ecosystem, sharing insights through publications such as the Omega Insights Series.

Boxer Capital is the corporate venture capital arm of Tavistock Group that concentrates its investments in biotechnology and life sciences. Based in San Diego, California, the firm pursues opportunities in both private and public biotechnology companies across the entire drug development lifecycle, from early discovery assets to late-stage clinical and commercial programs. It combines scientific expertise with investment experience to evaluate targets across therapeutic areas, emphasizes precision medicine, and seeks to support transformative medical advances through disciplined, research-driven analysis and active partnerships with portfolio companies.

EcoR1 Capital is a San Francisco-based investment firm focused on the biotechnology sector. It partners with entrepreneurs to fund and accelerate the development of novel therapeutics, translating scientific insight into strategic value for portfolio companies and aiming to bring life-saving medicines to patients. The firm seeks long-term collaborations across biology and chemistry to capture breakthroughs at the molecular level and expand the drug discovery toolkit.

Sofinnova Partners is an independent venture capital firm based in Paris, France, focused on life sciences. It invests in startups from seed to later stages in biopharmaceuticals, biotech, medical devices, industrial biotechnology, and related healthcare technologies. The firm often takes lead or cornerstone roles in rounds, sits on boards, and provides active support from formation onward to help entrepreneurs develop transformative innovations. It also considers corporate spin-offs and occasional turnaround opportunities, with the aim of delivering meaningful health advances alongside attractive returns for investors.

Mission BioCapital is a life science venture capital firm focused on early-stage investments in biotechnology and related life sciences in the United States, with offices in Cambridge, Massachusetts and San Francisco. The leadership team has a long history of launching dozens of early-stage life science companies and a track record of providing deep expertise and support to portfolio companies. The firm emphasizes mentorship, collaboration, and founder-centric value creation, and offers programs such as the Platinum Program, which provides up to $500,000 in funding along with lab space and services including drug discovery, legal and financial assistance to accelerate development.

Hercules Capital is a specialty finance company that acts as a non-bank lender and business development company, providing venture debt and related capital to venture-backed technology, life sciences, and sustainable technology companies. With more than a decade of experience, it offers senior secured and structured debt, often with warrants, to support growth, acquisitions, recapitalizations, and pre-IPO needs. The company focuses on cash-flow based financing and asset-based facilities such as accounts receivable lines, equipment loans, and working capital facilities, tailoring structures to fit a portfolio company's capital plan and milestones. It primarily serves United States based, venture-backed firms across software, hardware, healthcare, energy technology, and related sectors, spanning early to late-stage growth. The organization positions itself as a flexible partner that helps portfolio companies reach milestones and potentially pursue IPOs or M&A exits, backed by a diversified portfolio of hundreds of companies.

HBM Healthcare Investments is a Swiss investment company that concentrates on the global healthcare sector, seeking to capitalize on innovation across private and public healthcare companies. Founded in 2001 and based in Switzerland, it maintains a diversified portfolio spanning human medicine, biotechnology, medical technology and diagnostics, with investments across private companies, public equities, and funds. The firm emphasizes high-value creation potential through its portfolio and positions itself to benefit from demographic trends, medical advancements and rising demand for new therapies.

SR One is the corporate venture capital arm of GlaxoSmithKline, a trans-Atlantic biotechnology investor focused on funding innovative science to develop new medicines. It operates from biotechnology hubs on the West Coast and in London, leveraging its cross-Atlantic presence to provide strategic partnerships, geographic reach, and portfolio support that accelerates the translation of scientific breakthroughs into medicines. Founded in 1985, SR One has invested about 800 million dollars in more than 180 life science companies, and it employs a back-and-build approach that prioritizes strong scientific fundamentals, clear development plans, and novel approaches to disease treatment.

F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts, with a history spanning more than five decades and offices in London and San Francisco. It invests across healthcare and technology, including life sciences, therapeutics, medtech, healthtech and services, enterprise software, fintech, frontier tech, and crypto, with a global reach across the Americas, Europe, and Asia. The firm emphasizes backing ambitious teams at any stage and leverages a team of scientists, engineers, physicians, operators, and investors to support rapid, scalable growth. Known for thoughtful collaboration and a focus on impact, F-Prime leverages its experience to help portfolio companies navigate scientific, technical, and market challenges, aiming to drive breakthroughs in healthcare and technology and to advance bold, transformative ideas.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.

Kurma Partners is a Paris-based investment firm specializing in financing innovation in healthcare and biotechnology across Europe, from early development to growth-stage capital. Founded in 2009, it operates as a private equity and venture capital firm dedicated to funding therapeutic and medical innovations, and it maintains close collaboration with European academic researchers, hospitals, and institutes to translate scientific advances into medicines and medical devices. The firm supports portfolio companies through capital and strategic guidance, investing across healthcare, life sciences, digital health, and related technologies, and it maintains a network of partnerships to advance translational science, with a focus on sustainable development and ESG practices.

Commodore Capital is a New York-based venture capital firm founded in 2019 that concentrates on the biopharmaceutical sector. It focuses on early-stage opportunities within smaller biopharmaceutical companies, partnering to advance innovative modalities such as genetic medicines and cellular therapies. The firm aims to translate scientific discoveries into clinical breakthroughs that improve patients' lives by backing companies developing safe and effective medicines for patients worldwide.

Merck is a global pharmaceutical company focused on discovering, developing, and delivering medicines and vaccines to treat cancer, infectious diseases, and other conditions. It emphasizes oncology through its immuno-oncology platform, with Keytruda as a major product contributor, and maintains a substantial vaccine business that includes Gardasil to prevent human papillomavirus infections. The company also targets cardiometabolic, infectious, immunology, neuroscience, and ophthalmology areas, supported by a robust pipeline and clinical development efforts powered by data science and AI. Merck pursues responsible operations, sustainability initiatives, and patient access programs, while maintaining transparency with stakeholders. Its activities span global markets, with emphasis on innovative partnerships to expand healthcare impact and address unmet medical needs.

VenBio Partners is a California-based venture capital firm with offices in San Francisco and Seattle, focused on life sciences and investing across the development spectrum in the United States. The firm aims to lead most of its investments and actively builds syndicates and teams to support portfolio companies. It emphasizes positions that enable potential acquisition partners, prioritizing strong intellectual property, CMC capabilities, and clearly defined clinical development plans, including trial design, endpoints, powering, and regulatory considerations. VenBio provides strategic guidance throughout development to maximize impact and foster long-term relationships with leaders in the field.

SV Health Investors is a private equity and venture capital firm that focuses on healthcare and life sciences, including biotech, therapeutics, and medtech. Founded in 1993 as SV Life Sciences, the firm operates globally with offices in Boston, San Francisco, and London and maintains a long US and Europe track record. It funds companies across stages, partnering with entrepreneurs to build breakthrough treatments and technologies, and provides strategic guidance and industry expertise to help portfolio companies grow and pursue IPOs or strategic transactions. With a team of over 50 professionals, SV Health Investors emphasizes value creation across its healthcare investments and seeks to transform healthcare through its portfolio.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 by John Diekman and Andrew Schwab. It focuses on seed- and early-stage investments in life sciences and healthcare, including biopharmaceuticals, biotechnology, drug delivery, medical technology, and research instruments, with additional interest in digital health and health technology. The firm maintains a Boston office and targets opportunities across the United States and North America, partnering with academics and entrepreneurs to build next-generation life science companies. It also operates an internal initiative called 4:59 to identify, incubate, and fund breakthrough science.

Canaan Partners is a global early-stage venture capital firm founded in 1987 and headquartered in San Francisco. It focuses on supporting technology and healthcare startups at the seed and early stages, investing across sectors such as fintech, enterprise software and cloud, marketplaces, frontier technologies, biopharma, digital health and medtech. The firm maintains an international footprint with offices in Israel and India and backs entrepreneurs by leveraging a broad network of strategic partners, customers and follow-on investors to help transform innovative ideas into global companies.

High-Tech Gründerfonds is a Germany-based venture capital firm established in 2005 that funds early-stage technology startups in Germany. Based in Bonn with an office in Berlin, it supports companies across software, information technology, digital and industrial tech, life sciences, chemistry, IoT, energy, and related fields by providing initial capital and subsequent funding, complemented by active guidance from investment managers. The firm typically acts as a lead investor and cooperates with other investors to help portfolio companies advance from concept to market, with a focus on startups that have begun commercial operations. By combining financing with hands-on support, HTGF aims to help high-potential founders develop their technology, validate products, and scale within the German market.

Takeda Pharmaceutical is a global biopharmaceutical leader and Japan’s largest pharmaceutical company. It researches, develops, manufactures, and markets prescription medicines and vaccines across oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. The company serves patients worldwide with a diversified geographic footprint—roughly half of revenue from the United States, about 10% from Japan, 25% from Europe, and 15% from Canada. Takeda emphasizes patient-centered growth, sustainability, and ethical practices, supported by a strong focus on research and development to translate science into transformative medicines.

Ally Bridge Group is a private investment firm focused on healthcare and life sciences, with offices in New York and Hong Kong. Founded in 2013, it pursues venture, growth, private equity, and public equity investments across private and public markets in the United States, China, and Europe, targeting innovative drugs, medical devices, diagnostics, and digital health platforms. The firm combines scientific and clinical insight with capital markets expertise to bridge healthcare innovations with global markets, aiming to generate superior risk-adjusted returns while supporting portfolio companies through development and scale.

Casdin Capital is a New York-based investment firm focused on the life sciences and healthcare sectors. It targets biotechnology, genomics, precision medicine, oncology, digital health, and related technologies, applying data-driven, research-intensive analysis to identify disruptive opportunities in the field. The firm makes private investments across stages and seeks to partner with companies developing innovative therapies, diagnostics, and tools that advance healthcare. Founded in 2012 by Eli Casdin, Casdin Capital operates as a registered investment adviser and emphasizes a long-term, fundamental approach to identifying paradigm shifts in life sciences.

Abingworth is an international life sciences investment firm founded in 1973 with offices in London, Menlo Park, and Boston. It invests across the development spectrum—from seed-stage to publicly traded companies—and across sectors including healthcare, biotechnology, pharmaceuticals, and medical devices in the United States and Europe. The firm collaborates with life sciences entrepreneurs to translate scientific advances into health-impacting products, providing capital and strategic guidance through its portfolio companies. With over $1 billion under management and a dedicated team, Abingworth has backed more than 140 life science companies and supported many IPOs and strategic transactions, reflecting a focus on advancing therapeutics and related technologies.

Aisling Capital is a New York-based investment firm focused on healthcare and life sciences. Founded in 2000, it specializes in biopharmaceutical development and commercialization, investing in companies across the United States, Western Europe, and Canada. The firm supports mid- to late-stage ventures and growth companies seeking to advance therapies from discovery to commercialization, drawing on extensive healthcare industry experience. With more than $1.8 billion in assets and a track record across genomics-defined cancers, neuroscience and other central nervous system disorders, Aisling Capital aims to back global healthcare innovators and translate scientific breakthroughs into approved products.

Nextech Invest is a Zurich-based investment firm that targets early-stage healthcare and life sciences companies globally. It focuses on precision medicine and oncology, supporting ventures developing cancer therapies, diagnostics, and related technologies. The firm emphasizes scientific validation and value creation, provides targeted funding and strategic guidance, and seeks board positions in its portfolio companies. Active across Europe and beyond, it pursues interdisciplinary projects that blend biology, medicine and technology to accelerate development from discovery to market.

Pivotal bioVenture Partners is a San Francisco–based venture capital firm that specializes in life sciences and therapeutic devices. Founded in 2016, the firm funds privately held biotechnology, therapeutics, medical devices, diagnostics, and related services companies across North America, Europe, and Greater China. It invests across the company lifecycle, from creation through mid- and late-stage clinical development, and supports founders with a team that combines venture experience with drug discovery and development expertise. The firm operates through regional vehicles, including Pivotal BioVenture Partners China in Shanghai and other U.S. and European-focused funds, and manages more than three billion dollars in assets. Its strategy emphasizes advancing innovative products to address unmet medical needs and building new ventures that accelerate healthcare breakthroughs.

Frazier Healthcare Partners is a Seattle-based investment firm founded in 1991 that specializes in healthcare, operating through two divisions: Frazier Healthcare Partners, which targets broader healthcare companies, and Frazier Life Sciences, which focuses on biopharmaceutical discovery, development and commercialization. The firm pursues growth buyout investments in profitable US middle-market healthcare businesses and backs companies across the healthcare spectrum, including pharmaceuticals, biotechnology, healthcare services, medical devices and supplies, and related sectors. It invests in opportunities across the United States, Canada and Europe, and partners with industry executives to scale operations and drive transformative growth.